SCHEMBL31358796

SCHEMBL31358796

O=C1C(=Cc2ccc(-c3ccc(Cl)c([N+](=O)[O-])c3)o2)Sc2ccccc21

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN5 P54829 2/20 0.68
PTPN1 P18031 1/20 0.58
PTPN7 P35236 1/20 0.58
DUSP3 P51452 1/20 0.58
PTPN22 Q9Y2R2 1/20 0.58
INSR P06213 2/20 0.48
IGF1R P08069 2/20 0.48
GSK3A P49840 4/20 0.46
GSK3B P49841 4/20 0.46
CDK2 P24941 1/20 0.46
MAPT P10636 6/20 0.46
MEN1 O00255 4/20 0.46
KMT2A Q03164 4/20 0.46
POLB P06746 4/20 0.46
TDP1 Q9NUW8 3/20 0.46
LMNA P02545 2/20 0.46
CASP3 P42574 1/20 0.44
BLM P54132 1/20 0.44
SENP8 Q96LD8 1/20 0.44
SENP7 Q9BQF6 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31358761 0.83 PTPN5 (0.73) PTPN5PTPN1PTPN7DUSP3PTPN22
SCHEMBL31358763 0.83 PTPN5 (0.52) PTPN5PTPN1PTPN7DUSP3PTPN22
SCHEMBL31358797 0.83 KMT2A (0.56) PTPN5MAPTMEN1KMT2APOLB
SCHEMBL31358736 0.83 INSR (0.67) PTPN5PTPN1PTPN7DUSP3PTPN22
SCHEMBL31358807 0.83 INSR (0.53) PTPN5PTPN1PTPN7DUSP3PTPN22
SCHEMBL31358666 0.83 GSK3A (0.63) PTPN5PTPN1PTPN7DUSP3PTPN22
SCHEMBL31358747 0.81 PTPN5 (0.70) PTPN5PTPN1PTPN7DUSP3PTPN22
SCHEMBL31358787 0.81 PTPN5 (0.68) PTPN5PTPN1PTPN7DUSP3PTPN22
SCHEMBL31358818 0.81 PTPN5 (0.68) PTPN5PTPN1PTPN7DUSP3PTPN22
SCHEMBL31358713 0.81 PTPN5 (0.68) PTPN5PTPN1PTPN7DUSP3PTPN22

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250026741-A1 INHIBITORS OF THE ONCOGENIC SHP2 PHOSPHATASE AND USES THEREOF Sanford Burnham Prebys Medical Discovery Institute 2025-01-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250026741-A1 INHIBITORS OF THE ONCOGENIC SHP2 PHOSPHATASE AND USES THEREOF PTPN18, PTPN7, PTPN1 PTPN5 8/4885PTPN1 3/4885PTPN7 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.